Enhanced cytotoxicity of Rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins

Leukemia and Lymphoma

Volumn 45, Issue 4, 2004, Pages 795-800

  Nagajothi, Nagaprasad ^a   Matsui, William H ^a   Mukhina, Galina L ^a   Brodsky, Robert A ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Division of Hematologic Malignancies   (United States)

Author keywords

Complement dependent cytoxicity; GPI anchored proteins; Mechanism of action; Rituximab

Indexed keywords

GLYPICAN; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; RITUXIMAB;

ARTICLE; CELL DEATH; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SOMATIC MUTATION;

EID: 1342266138     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001625700     Document Type: Article

References (25)

1. Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., et al. (1997) "IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma". Journal of Clinical Oncology, 15, 3266-3274.
2. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., et al. (1997) "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma". Blood, 90, 2188-2195.
3. Levine, T.D. and Pestronk, A. (1999) "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab". Neurology, 52, 1701-1704.
4. Stasi, R., Pagano, A., Stipa, E. and Amadori, S. (2001) "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura". Blood, 98, 952-957.
5. Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., et al. (2000) "European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma". Journal of Clinical Oncology, 18, 317-324.
6. Scallon, B.J., Moore, M.A., Trinh, H., Knight, D.M. and Ghrayeb, J. (1995) "Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions". Cytokine, 7, 251-259.
7. Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., et al. (2000) "Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis". Blood, 95, 3900-3908.
8. Harjunpaa, A., Junnikkala, S. and Meri, S. (2000) "Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms". Scandinavian Journal of Immunology, 51, 634-641.
9. Treon, S.P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., et al. (2001) "Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies". Journal of Immunotherapy, 24, 263-271.
10. Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., et al. (2001) "CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59". Blood, 98, 3383-3389.
11. Miyata, T., Takeda, J., Iida, Y., Yamada, N., Inoue, N., Takahashi, M., et al. (1993) "The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis". Science, 259, 1318-1320.
12. Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., et al. (1993) "Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria". Cell, 73, 703-711.
13. Miyata, T., Yamada, N., Iida, Y., Nishimura, J., Takeda, J., Kitani, T., et al. (1994) "Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria". New England Journal of Medicine, 330, 249-255.
14. Bessler, M., Mason, P.J., Hillmen, P., Miyata, T., Yamada, N., Takeda, J., et al. (1994) "Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene". The EMBO Journal, 13, 110-117.
15. Nagarajan, S., Brodsky, R.A., Young, N.S. and Medof, M.E. (1995) "Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia". Blood, 86, 4656-4661.
16. Rosse, W.F. and Ware, R.E. (1995) "The molecular basis of paroxysmal nocturnal hemoglobinuria". Blood, 86, 3277-3286.
17. Rosse, W.F. (1997) "Paroxysmal nocturnal hemoglobinuria as a molecular disease". Medicine, 76, 63-93.
18. Venneker, G.T., Vodegel, R.M., Okada, N., Westerhof, W., Bos, J,D. and Asghar, S.S. (1998) "Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement". Immunobiology, 198, 476-484.
19. Brodsky, R.A., Vala, M.S., Barber, J.P., Medof, M.E. and Jones, R.J. (1997) "Resistance to Apoptosis Caused by PIG-A Gene Mutations in Paroxymal Nocturnal Hemoglobinuria". Proceedings of the National Academy of Sciences of the United States of America, 94, 8756-8760.
20. Brodsky, R.A., Jane, S.M., Vanin, E.F., Mitsuya, H., Peters, T.R., Shimada, T., et al. (1995) "Purified GPI-anchored CD4DAF as a receptor for HIV-mediated gene transfer". Human Gene Therapy, 5, 1231-1239.
21. Treon, S.P., Pilarski, L.M., Belch, A.R., Kelliher, A., Preffer, F.I., Shima, Y., et al. (2002) "Anderson, K.C., CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications". Journal of Immunotherapy, 25, 72-81.
22. Medof, M.E., Kinoshita, T. and Nussenzweig, V. (1994) "Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes". The Journal of Experimental Medicine, 160, 1558-1578.
23. Wilcox, L.A., Ezzell, J.L., Bernshaw, N.J., Parker, C.J. (1991) "Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum". Blood, 78[3], 820-829.
24. Holt, D.S., Botto, M., Bygrave, A.E., Hanna, S.M., Walport, M.J. and Morgan, B.P. (2001) "Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria". Blood, 98, 442-449.
25. Derigs, H.G. (2000) "In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs". Cytotherapy, 2, 445-453.